Sign In
News Digest /
Ticker: BMY
Ticker: BMY
03:27am, Tuesday, May 12, 2026
Jiangsu Hengrui Pharmaceuticals' shares soared after announcing a global oncology and immunology development deal with Bristol-Myers Squibb worth up to $15.2 billion.
11:04am, Tuesday, Jan 20, 2026
Bristol Myers Squibb collaborates with Microsoft to deploy AI-enhanced radiology tools aimed at earlier, more accurate lung cancer diagnosis, focusing on underserved US communities.
09:18am, Friday, Nov 14, 2025
Bristol-Myers Squibb cuts its Phase 3 Librexia ACS trial for milvexian after interim analysis signals low chance of success, causing a 5.2% premarket stock dip.
09:12am, Tuesday, Nov 04, 2025
Pfizer outperforms Q3 earnings forecasts and raises full-year profit guidance even as sales decline, driven by strategic cost cuts and ongoing challenges in the Covid product line.
01:07pm, Thursday, Jul 31, 2025
Company Overview
Bristol-Myers Squibb (NYSE: BMY) continues to navigate a complex landscape as it aims to enhance its portfolio and adapt to market challenges. As of June 30, 2025, the company reported a modest increase in total revenues of 1% in Q2 2025, but a decline of 2% year-to-date compared...
09:09am, Thursday, Jun 26, 2025
Incyte (NASDAQ: INCY) shares rose 3.6% following Bill Meury's appointment as CEO, succeeding Hervé Hoppenot. With 30 years of industry experience, Meury aims to enhance R&D and growth. Traders should monitor Incyte for potential advancements in its product lineup.
08:30am, Friday, May 30, 2025
Shares of Regeneron Pharmaceuticals (NASDAQ: REGN) plummeted nearly 9% in pre-market trading after mixed results from its COPD treatment trial, itepekimab. Analysts express concerns about its market viability against Dupixent, raising uncertainties for investors.
12:01pm, Thursday, Apr 24, 2025
Bristol-Myers Squibb Company (NYSE: BMY) has recently released its quarterly report for the period ending March 31, 2025. Below are key highlights and takeaways, reflecting both positive and negative aspects of the company's income statement.
Total Revenues: $11.201 billion, a decrease of 5.6% f...